Literature DB >> 11870243

The prevalence of proteolytic antibodies against factor VIII in hemophilia A.

Sébastien Lacroix-Desmazes1, Jagadeesh Bayry, Namita Misra, Michael P Horn, Sylvie Villard, Anastas Pashov, Natalie Stieltjes, Roseline d'Oiron, Jean-Marie Saint-Remy, Johan Hoebeke, Michel D Kazatchkine, Joseph Reinbolt, Dipika Mohanty, Srini V Kaveri.   

Abstract

BACKGROUND: Factor VIII inhibitors are IgG alloantibodies that arise during replacement therapy in 25 to 50 percent of patients with severe hemophilia A. The hydrolysis of factor VIII by anti--factor VIII antibodies has been proposed as a mechanism of inactivation of factor VIII.
METHODS: We purified IgG from patients with severe hemophilia A. The proteolytic activity of the antibodies was assessed by incubating the IgG with biotinylated human factor VIII and analyzing patterns of factor VIII cleavage by sodium dodecyl sulfate--polyacrylamide-gel electrophoresis and immunoblotting. The controls were normal human IgG and IgG purified from plasma of patients with hemophilia who did not have inhibitory antibodies.
RESULTS: Significant proteolytic activity was detected in IgG from 13 of 24 inhibitor-positive patients. No hydrolytic activity was detected in control antibodies of IgG from patients without inhibitors. The rate of hydrolysis of factor VIII by purified IgG correlated positively with the factor VIII--neutralizing activity of IgG in plasma (r2=0.67, P=0.029). Principal-component analysis of migration profiles of digestion fragments demonstrated the heterogeneity of the catalytic potential of factor VIII inhibitors among patients.
CONCLUSIONS: Proteolysis is a mechanism by which IgG antibodies against factor VIII can inactivate factor VIII.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11870243     DOI: 10.1056/NEJMoa011979

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  21 in total

1.  High levels of catalytic antibodies correlate with favorable outcome in sepsis.

Authors:  Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri; David Hayon-Sonsino; Nithyananda Thorenoor; Julien Charpentier; Charles-Edouard Luyt; Jean-Paul Mira; Valakunja Nagaraja; Michel D Kazatchkine; Jean-François Dhainaut; Vincent O Mallet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

2.  Anti-factor VIII antibodies (Inhibitors) in hemophilia A: in dire need of basic and therapeutic research.

Authors:  Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

3.  Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.

Authors:  M V Ragni; O Ojeifo; J Feng; J Yan; K A Hill; S S Sommer; M N Trucco; D J Brambilla
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

4.  A human germ line antibody light chain with hydrolytic properties associated with multimerization status.

Authors:  Vikram Sharma; William Heriot; Kirk Trisler; Vaughn Smider
Journal:  J Biol Chem       Date:  2009-10-02       Impact factor: 5.157

Review 5.  Autoantibodies with enzymatic properties in human autoimmune diseases.

Authors:  Bharath Wootla; Sébastien Lacroix-Desmazes; Arthur E Warrington; Allan J Bieber; Srini V Kaveri; Moses Rodriguez
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

6.  A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

Authors:  Giovanni Di Minno; Antonio Coppola
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

Review 7.  Treatment of patients with haemophilia and inhibitory antibodies.

Authors:  P L F Giangrande
Journal:  Indian J Pediatr       Date:  2003-08       Impact factor: 1.967

Review 8.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

9.  Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients.

Authors:  Ankit Mahendra; Ivan Peyron; Olivier Thaunat; Cécile Dollinger; Laurent Gilardin; Meenu Sharma; Bharath Wootla; Desirazu N Rao; Séverine Padiolleau-Lefevre; Didier Boquet; Abhijit More; Navin Varadarajan; Srini V Kaveri; Christophe Legendre; Sébastien Lacroix-Desmazes
Journal:  J Immunol       Date:  2016-04-11       Impact factor: 5.422

10.  Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.

Authors:  Jinhai Wang; Jay Lozier; Gibbes Johnson; Susan Kirshner; Daniela Verthelyi; Anne Pariser; Elizabeth Shores; Amy Rosenberg
Journal:  Nat Biotechnol       Date:  2008-08       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.